Featured Research

from universities, journals, and other organizations

Drug-resistant Tuberculosis Rises, But New Treatments In The Pipeline

Date:
September 27, 2007
Source:
American Chemical Society
Summary:
An arsenal of promising new medications, vaccines, and diagnostic tests are moving toward the global battlefield that pits medicine against drug-resistant tuberculosis (TB), which is claiming a terrible toll, particularly in HIV-infected individuals, according to a new article. There are now far-ranging efforts underway to develop new TB diagnostic tests and treatments. For years, conventional treatments for TB had slowed the spread of the disease, but the emergence of new drug-resistant strains has reduced the effectiveness of those medications.

An arsenal of promising new medications, vaccines, and diagnostic tests are moving toward the global battlefield that pits medicine against drug-resistant tuberculosis (TB), which is claiming a terrible toll, particularly in HIV-infected individuals, according to a new article.

In Chemical & Engineering News, senior correspondent Ann Thayer and assistant editor Carmen Drahl describe far-ranging efforts underway to develop new TB diagnostic tests and treatments.

For years, conventional treatments for TB had slowed the spread of the disease, but the emergence of new drug-resistant strains has reduced the effectiveness of those medications.

Researchers are developing more accurate diagnostic tests, new drugs to fight multidrug resistant strains, and ones that are more compatible with individuals who are undergoing treatment for HIV. Scientists are also developing more effective vaccines, including those that might show promise for both preventing and treating the disease, Thayer notes.

"In the past five years or so, the TB drug pipeline has shifted from nearly empty to having about 30 compounds under investigation; several are in early clinical testing," Thayer writes.

The article, "Taking Down TB," is scheduled for publication Sept. 24.


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Drug-resistant Tuberculosis Rises, But New Treatments In The Pipeline." ScienceDaily. ScienceDaily, 27 September 2007. <www.sciencedaily.com/releases/2007/09/070924092604.htm>.
American Chemical Society. (2007, September 27). Drug-resistant Tuberculosis Rises, But New Treatments In The Pipeline. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/09/070924092604.htm
American Chemical Society. "Drug-resistant Tuberculosis Rises, But New Treatments In The Pipeline." ScienceDaily. www.sciencedaily.com/releases/2007/09/070924092604.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins